Salud financiera de hoja de balance de Basilea Pharmaceutica

Salud financiera controles de criterios 5/6

Basilea Pharmaceutica tiene un patrimonio de los accionistas total de CHF16.8M y una deuda total de CHF95.7M, lo que sitúa su ratio deuda-patrimonio en 570%. Sus activos y pasivos totales son CHF188.7M y CHF171.9M respectivamente.

Información clave

570.0%

Ratio deuda-patrimonio

CHF 95.68m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	CHF 62.96m
Patrimonio	CHF 16.79m
Total pasivo	CHF 171.88m
Activos totales	CHF 188.66m

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Apr 18

Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Sep 20

Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Feb 17

Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Jul 01

Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

Mar 24

If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

Feb 18

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CHF155.0M) de BSLN superan a sus pasivos a corto plazo (CHF37.8M).

Pasivo a largo plazo: Los activos a corto plazo de BSLN (CHF155.0M) superan a sus pasivos a largo plazo (CHF134.1M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de BSLN (194.9%) se considera alta.

Reducción de la deuda: BSLN tenía patrimonio neto negativo hace 5 años, pero ahora es positivo y, por lo tanto, ha mejorado.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: Aunque no es rentable BSLN tiene suficiente cash runway para más de 3 años si mantiene su actual nivel positivo de flujo de caja libre.

Pronóstico de cash runway: BSLN no es rentable pero tiene suficiente cash runway para más de 3 años, debido a que el flujo de caja libre es positivo y crece un 40.5% al año.

Salud financiera de hoja de balance de Basilea Pharmaceutica

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Basilea Pharmaceutica AG Updates Financial Guidance for the Year 2024

European Commission Approves the Pediatric Use of Basilea Pharmaceutica AG's Antifungal Cresemba® (Isavuconazole)

First half 2024 earnings: EPS exceeds analyst expectations

New minor risk - Share price stability

Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Consensus EPS estimates increase by 15%

Price target increased by 7.6% to CHF70.58

Basilea Pharmaceutica AG to Report First Half, 2024 Results on Aug 13, 2024

New minor risk - Negative shareholders equity

Full year 2023 earnings: EPS exceeds analyst expectations

New minor risk - Share price stability

Consensus EPS estimates fall by 78%

Price target decreased by 7.6% to CHF69.90

Consensus EPS estimates fall by 30%

Basilea Pharmaceutica AG to Report Fiscal Year 2023 Results on Feb 13, 2024

Basilea Pharmaceutica AG, Annual General Meeting, Apr 24, 2024

Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Basilea Pharmaceutica AG Revises Earnings Guidance for the Year 2023

First half 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Price target decreased by 9.0% to CHF67.18

Consensus EPS estimates increase by 13%

Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Basilea Pharmaceutica AG to Report First Half, 2023 Results on Aug 15, 2023

Basilea Pharmaceutica Ltd Revises Earnings Guidance for the Year 2022

Basilea Pharmaceutica AG, Annual General Meeting, Apr 26, 2023

Basilea Pharmaceutica AG to Report Fiscal Year 2022 Results on Feb 14, 2023

Price target decreased to CHF68.58

Price target decreased to CHF68.58

Basilea Pharmaceutica AG 's ERADICATE Phase 3 Study Results Highlight the Potential Role of Ceftobiprole in the Treatment of Staphylococcus Aureus Bacteremia (Sab)

Consensus estimates of losses per share improve by 13%

Consensus estimates of losses per share improve by 10%

Basilea Pharmaceutica AG Revises Earnings Guidance for the Full Year 2022

Price target increased to CHF73.98

First half 2022 earnings: EPS and revenues exceed analyst expectations

Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2022

Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2022

Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Consensus forecasts updated

Basilea Pharmaceutica Ltd. Positive Results of Phase 3 Eradicate Study with Ceftobiprole in Staphylococcus Aureus Bacteremia

Basilea Pharmaceutica AG Reports Progress on the Implementation of Its Strategy to Focus on Anti-Infectives

Basilea Pharmaceutica AG to Report First Half, 2022 Results on Aug 16, 2022

High number of new directors

Price target decreased to CHF77.00

Insufficient new directors

Basilea Pharmaceutica Ltd. Approves Appointment of Leonard Kruimer as New Member of Board and as Chairman of the Audit Committee

Basilea Pharmaceutica Ltd. Reports Preclinical Data on Oncology Drug Candidates BAL0891

Price target decreased to CHF77.50

Basilea Reports Preclinical Data on Anti-Cancer Activity of Novel Oncology Drug Candidate BAL0891 at ESMO TAT congress

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Forecast breakeven date moved forward to 2023

Basilea Pharmaceutica AG Provides Earnings Guidance for the Fiscal Year 2022

Basilea Reports Updated Interim Results for iCCA Patients with FGFR2 Mutations and Amplifications from Phase 2 Study FIDES-01 at ASCO GI Cancers Symposium

Basilea Announces Completion of Patient Enrolment in Phase 3 Eradicate Study Investigating Ceftobiprole in Bloodstream Infections

Forecast to breakeven in 2024

Basilea Pharmaceutica Ltd. Announces FDA Approval of Investigational New Drug Application for Novel Oncology Drug Candidate BAL0891

Basilea Pharmaceutica Ltd. Presents Full Safety and Efficacy Data Set on Derazantinib in Patients with FGFR2 Fusion-Positive iCCA at ESMO Congress

First half 2021 earnings released: CHF1.72 loss per share (vs CHF0.92 profit in 1H 2020)

No longer forecast to breakeven

Basilea Pharmaceutica Ltd. Provides Updates on Efficacy Data with Derazantinib in Bile Duct Cancer and on Ongoing Clinical Programs in Urothelial and Gastric Cancer

Basilea Pharmaceutica AG Wins Carb-X Grant of Up to USD 2.7 Million to Develop Novel-Class Antibiotic

Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

Basilea Pharmaceutica AG has completed a Follow-on Equity Offering in the amount of CHF 45.75 million.

If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

PHT International Inc. entered into an agreement to acquire Basilea Pharmaceutica China Ltd. from Basilea Pharmaceutica AG (SWX:BSLN) for $6.3 million.

Basilea Pharmaceutica Ltd. Reports derazantinib/PD-L1 Checkpoint Inhibitor Combination Results from Dose-Finding Part of FIDES-02 Study in Patients with Solid Tumors at ASCO GU Symposium

Basilea Pharmaceutica Ltd. Promotes Potential First-In-Class Small-Molecule Kinase Inhibitor

New 90-day high: CHF58.60

Analysts update estimates

Basilea Pharmaceutica Ltd. Reports Positive Topline Results from Phase 2 Study FIDES-01 for Derazantinib in FGFR2 Gene Fusion-Positive Patients with Bile Duct Cancer (iCCA)

New 90-day high: CHF55.65

Basilea Pharmaceutica AG to Report Fiscal Year 2020 Results on Feb 16, 2021

New 90-day high: CHF52.90